Free press releases distribution network?

Agency / Source: FTPB (French Technology Press Bureau)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement - IN CELL ART, a biotechnology company involved in macromolecular drug (siRNA, DNA, proteins) delivery systems, has announced that the company has entered into a research collaboration agreement with Sanofi Pasteur
IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement

 

PRZOOM - /newswire/ - London, United Kingdom, 2008/09/09 - IN CELL ART, a biotechnology company involved in macromolecular drug (siRNA, DNA, proteins) delivery systems, has announced that the company has entered into a research collaboration agreement with Sanofi Pasteur.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

IN CELL ART, announced that the company has entered into a research collaboration agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, to evaluate IN CELL ART nanocarriers’ technologies in the context of Sanofi Pasteur’s vaccines programme. Convincing results arising from such studies should lead to the continuation of IN CELL ART nanocarriers’ evaluation in Sanofi Pasteur’s new vaccines development.

IN CELL ART offers a range of biotechnology development services. The French company has expertise in antibody generation using genetic immunisation, allowing for the rapid synthesis of antibodies to any gene-specific antigen. This technology is particularly suitable for screening applications, which lead to the identification of antibodies of therapeutic interest.

IN CELL ART is also pursuing highly promising approaches in the field of DNA-based therapeutic and prophylactic vaccines, with successful studies in animal models of cancers and infectious diseases. IN CELL ART works in partnership with pharmaceutical and biotechnology companies and grants licences for its vaccine formulation.

With ongoing R&D programmes in the fields of oncology, as well as cardiovascular and anti-infectious diseases, IN CELL ART also works closely with companies that are active in the development of RNAi therapeutic products for interference with the expression of targeted disease-associated genes. Besides, IN CELL ART works with companies involved in the development of therapeutic proteins for the improvement of pharmacokinetics. In both these areas, IN CELL ART grants licences for its nanocarriers.

Finally, IN CELL ART is commercializing ICAFectin®441 and ICAFectin®442, which are DNA and siRNA transfection reagents for primary and stem cells.

About IN CELL ART

IN CELL ART (incellart.com), which is headquartered in Nantes (in western France), is a biopharmaceutical company specialising in the preclinical and pharmaceutical development of nanocarriers for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organised on a nanometric scale, which enables them to cross the cell barrier efficiently and safely.

IN CELL ART is a privately held company, which was founded in 2005. It is a member of the Atlantic Biotherapies high-tech cluster of biotechnology companies in western France.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: FTPB (French Technology Press Bureau)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Kate Ambler - UBIFRANCE.fr 
+44(0)20 7235 5330 contact.ftpb[.]ubifrance.fr
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any FTPB (French Technology Press Bureau) securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From FTPB (French Technology Press Bureau) / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today